Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ABT?
Source: Newsfilter
- Acquisition Completed: Abbott announced the completion of its acquisition of Exact Sciences on March 20, 2026, establishing itself as a leader in the cancer screening and diagnostics sector, which is expected to enhance healthcare access for millions and strategically position the company in a rapidly growing market.
- Market Potential: This transaction allows Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, adding a new growth vertical that is anticipated to elevate the company's already high-single-digit growth expectations and strengthen its competitive edge.
- Expanded Product Portfolio: Abbott now boasts a comprehensive suite of leading cancer early detection products, including the market-leading Cologuard® and Oncotype DX®, which will support personalized treatment decisions and improve patient outcomes and quality of life.
- Future Development Outlook: Following the acquisition, Abbott plans to leverage Exact Sciences' expertise to drive the development of more preventative and personalized diagnostic tools, aiming to optimize treatment decisions and enable earlier cancer detection, thereby enhancing overall health management capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 104.850
Low
136.00
Averages
148.11
High
169.00
Current: 104.850
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Completes Acquisition of Exact Sciences, Enhancing Cancer Diagnostics Leadership
- Acquisition Finalized: Abbott completed the acquisition of Exact Sciences on March 20, 2026, making it a wholly owned subsidiary and marking Abbott's leadership in the rapidly growing cancer screening and diagnostics sector.
- Market Expansion: This transaction positions Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, which is expected to drive the company towards high-single-digit growth expectations, enhancing its competitive edge.
- Enhanced Product Portfolio: Abbott now boasts a comprehensive suite of products, including Cologuard® and Oncotype DX®, focused on early cancer detection and personalized treatments, significantly strengthening its technological advantage in cancer care.
- Future Growth Potential: Post-acquisition, Abbott plans to leverage Exact Sciences' expertise to develop more preventative and personalized diagnostic tools, aiming to improve treatment outcomes and quality of life for cancer patients.
See More
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening
- Acquisition Completed: Abbott announced the completion of its acquisition of Exact Sciences on March 20, 2026, establishing itself as a leader in the cancer screening and diagnostics sector, which is expected to enhance healthcare access for millions and strategically position the company in a rapidly growing market.
- Market Potential: This transaction allows Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, adding a new growth vertical that is anticipated to elevate the company's already high-single-digit growth expectations and strengthen its competitive edge.
- Expanded Product Portfolio: Abbott now boasts a comprehensive suite of leading cancer early detection products, including the market-leading Cologuard® and Oncotype DX®, which will support personalized treatment decisions and improve patient outcomes and quality of life.
- Future Development Outlook: Following the acquisition, Abbott plans to leverage Exact Sciences' expertise to drive the development of more preventative and personalized diagnostic tools, aiming to optimize treatment decisions and enable earlier cancer detection, thereby enhancing overall health management capabilities.
See More
ABBOTT FINALIZES PURCHASE OF EXACT SCIENCES
- Acquisition Announcement: A company has completed the acquisition of Exact Sciences, enhancing its capabilities in the healthcare sector.
- Strategic Goals: The acquisition aims to leverage Exact Sciences' expertise to improve diagnostic solutions and expand market reach.
- Market Impact: This move is expected to strengthen the company's position in the competitive landscape of medical diagnostics.
- Future Plans: The company plans to integrate Exact Sciences' technologies and resources to drive innovation and growth in its product offerings.
See More
Defensive Stock Investment Recommendations
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
See More
Defensive Stocks to Strengthen Your Portfolio
- Abbott's Diversification Advantage: Abbott Laboratories operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—allowing it to maintain stable revenue growth during economic fluctuations, with diagnostics revenue surging during the pandemic and now driven by medical devices.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market downturns on their portfolios.
- Intuitive Surgical's Competitive Edge: As the global leader in robotic surgery, Intuitive Surgical's Da Vinci surgical robots command a high price, ensuring hospitals remain loyal to these devices to amortize their investment, thereby creating a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sale of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain financial stability during market downturns and reinforces its leadership position in the healthcare sector.
See More
Health Care Stocks Decline Late Friday
- Overall Decline: Late Friday, the NYSE Health Care Index experienced a downturn, indicating increasing market concerns about the healthcare sector, which may negatively impact investor confidence.
- Market Reaction: The decline in healthcare stocks may be linked to overall economic uncertainty, as investors anticipate potential policy changes that could lead to capital outflows from the sector, thereby affecting stock performance.
- Industry Impact: The weak performance of the healthcare sector could hinder related companies' financing capabilities and market valuations, especially under the current economic conditions where operational pressures are heightened.
- Investor Strategy Adjustment: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors with greater growth potential to mitigate risks associated with market volatility.
See More
Abbott Completes Acquisition of Exact Sciences, Enhancing Cancer Diagnostics Leadership
- Acquisition Finalized: Abbott completed the acquisition of Exact Sciences on March 20, 2026, making it a wholly owned subsidiary and marking Abbott's leadership in the rapidly growing cancer screening and diagnostics sector.
- Market Expansion: This transaction positions Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, which is expected to drive the company towards high-single-digit growth expectations, enhancing its competitive edge.
- Enhanced Product Portfolio: Abbott now boasts a comprehensive suite of products, including Cologuard® and Oncotype DX®, focused on early cancer detection and personalized treatments, significantly strengthening its technological advantage in cancer care.
- Future Growth Potential: Post-acquisition, Abbott plans to leverage Exact Sciences' expertise to develop more preventative and personalized diagnostic tools, aiming to improve treatment outcomes and quality of life for cancer patients.
See More
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening
- Acquisition Completed: Abbott announced the completion of its acquisition of Exact Sciences on March 20, 2026, establishing itself as a leader in the cancer screening and diagnostics sector, which is expected to enhance healthcare access for millions and strategically position the company in a rapidly growing market.
- Market Potential: This transaction allows Abbott to enter the $60 billion U.S. cancer screening and precision oncology diagnostics market, adding a new growth vertical that is anticipated to elevate the company's already high-single-digit growth expectations and strengthen its competitive edge.
- Expanded Product Portfolio: Abbott now boasts a comprehensive suite of leading cancer early detection products, including the market-leading Cologuard® and Oncotype DX®, which will support personalized treatment decisions and improve patient outcomes and quality of life.
- Future Development Outlook: Following the acquisition, Abbott plans to leverage Exact Sciences' expertise to drive the development of more preventative and personalized diagnostic tools, aiming to optimize treatment decisions and enable earlier cancer detection, thereby enhancing overall health management capabilities.
See More
ABBOTT FINALIZES PURCHASE OF EXACT SCIENCES
- Acquisition Announcement: A company has completed the acquisition of Exact Sciences, enhancing its capabilities in the healthcare sector.
- Strategic Goals: The acquisition aims to leverage Exact Sciences' expertise to improve diagnostic solutions and expand market reach.
- Market Impact: This move is expected to strengthen the company's position in the competitive landscape of medical diagnostics.
- Future Plans: The company plans to integrate Exact Sciences' technologies and resources to drive innovation and growth in its product offerings.
See More
Defensive Stock Investment Recommendations
- Abbott's Diversification: Abbott Laboratories (ABT) operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—ensuring that challenges in one area can be offset by growth in others, thus maintaining stable revenue performance amid economic fluctuations.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market volatility on their portfolios.
- Intuitive Surgical's Competitive Edge: Intuitive Surgical (ISRG) is the global leader in robotic surgery, with its Da Vinci surgical robots contributing to a solid earnings growth track record, and the fact that most surgeons are trained on these systems creates a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sales of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain robust financial performance even during market downturns.
See More
Defensive Stocks to Strengthen Your Portfolio
- Abbott's Diversification Advantage: Abbott Laboratories operates across four business units—medical devices, diagnostics, nutrition, and established pharmaceuticals—allowing it to maintain stable revenue growth during economic fluctuations, with diagnostics revenue surging during the pandemic and now driven by medical devices.
- Consistent Dividend Growth: As a Dividend King, Abbott has increased its dividend payments for over 50 consecutive years, providing investors with a reliable source of passive income that mitigates the impact of market downturns on their portfolios.
- Intuitive Surgical's Competitive Edge: As the global leader in robotic surgery, Intuitive Surgical's Da Vinci surgical robots command a high price, ensuring hospitals remain loyal to these devices to amortize their investment, thereby creating a strong market moat.
- Recurring Revenue Model: Intuitive Surgical generates most of its revenue from the sale of accessories and instruments needed for surgeries, establishing a recurring revenue stream that helps maintain financial stability during market downturns and reinforces its leadership position in the healthcare sector.
See More
Health Care Stocks Decline Late Friday
- Overall Decline: Late Friday, the NYSE Health Care Index experienced a downturn, indicating increasing market concerns about the healthcare sector, which may negatively impact investor confidence.
- Market Reaction: The decline in healthcare stocks may be linked to overall economic uncertainty, as investors anticipate potential policy changes that could lead to capital outflows from the sector, thereby affecting stock performance.
- Industry Impact: The weak performance of the healthcare sector could hinder related companies' financing capabilities and market valuations, especially under the current economic conditions where operational pressures are heightened.
- Investor Strategy Adjustment: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors with greater growth potential to mitigate risks associated with market volatility.
See More
